Advertisement

Topics

Novartis Delighted With Xiidra Deal Despite Eye-Watering Price

07:05 EDT 9 May 2019 | SCRIP

Shire got hold of the eyedrop product in 2013 through its acquisition of SARcode which cost $160m and despite struggling...

      

Related Stories

 

Original Article: Novartis Delighted With Xiidra Deal Despite Eye-Watering Price

NEXT ARTICLE

More From BioPortfolio on "Novartis Delighted With Xiidra Deal Despite Eye-Watering Price"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...